8-K – 2026-05-06 – uthr-20260506.htm

uthr-20260506 0001082554 false 0001082554 2026-05-06 2026-05-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________
 
FORM  8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):   May 6, 2026
 
United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)

Delaware 000-26301 52-1984749
(State or Other
Jurisdiction of
Incorporation) (Commission
File Number) (I.R.S. Employer
Identification Number)

 

1000 Spring Street  
Silver Spring,
MD 20910
(Address of Principal Executive Offices) (Zip Code)

 
Registrant’s telephone number, including area code:
( 301 ) 608-9292
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of exchange on which registered
Common Stock, par value $0.01 per share UTHR Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   ☐   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02.     Results of Operations and Financial Condition.
 
On May 6, 2026, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended March 31, 2026.
 
A copy of the press release is attached hereto as Exhibit 99.1.
 
Item 9.01.     Exhibits
 
This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
(d)  Exhibits
 

Exhibit No.   Description of Exhibit
   
99.1
Press Release dated May 6 , 202 6

104  The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

  UNITED THERAPEUTICS CORPORATION
   
 
Dated: May 6, 2026 By: /s/ Paul A. Mahon
  Name: Paul A. Mahon
  Title: General Counsel